The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Cytotoxic T-cell based cancer immunotherapy. Buy the report here.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
Cytotoxic T-cell based cancer immunotherapy is a key innovation area in immuno-oncology
Cytotoxic T-cell cancer therapy is a type of adoptive immunotherapy that makes immune cells to attack cancer cells. Patient’s T-cells are collected and expanded in the lab. The activated cancer-specific T cells are then reinfused into the patient’s bloodstream and kill cancer cells by recognising antigens expressed on their surface. Two main types of T-cell transfer therapy are tumour-infiltrating lymphocytes (or TIL) therapy and CAR T-cell therapy.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 180+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of cytotoxic T-cell based cancer immunotherapy.
Key players in cytotoxic T-cell based cancer immunotherapy – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to cytotoxic T-cell based cancer immunotherapy
|Company||Total patents (2010 - 2022)||Premium intelligence on the world's largest companies|
|Immatics||2033||Unlock Company Profile|
|OncoTherapy Science||492||Unlock Company Profile|
|Cellectis||330||Unlock Company Profile|
|Bristol-Myers Squibb||324||Unlock Company Profile|
|Iovance Biotherapeutics||298||Unlock Company Profile|
|Memorial Sloan Kettering Cancer Center||180||Unlock Company Profile|
|Immunovative Therapies||147||Unlock Company Profile|
|Fred Hutchinson Cancer Research Center||117||Unlock Company Profile|
|Gilead Sciences||112||Unlock Company Profile|
|Autolus||103||Unlock Company Profile|
|bluebird bio||92||Unlock Company Profile|
|Seattle Children's Hospital||86||Unlock Company Profile|
|ImmunityBio||71||Unlock Company Profile|
|City of Hope||70||Unlock Company Profile|
|Innovative Cellular Therapeutics||67||Unlock Company Profile|
|Vaccinex||59||Unlock Company Profile|
|Fate Therapeutics||58||Unlock Company Profile|
|Celularity||57||Unlock Company Profile|
|Sangamo Therapeutics||53||Unlock Company Profile|
|EpiVax||51||Unlock Company Profile|
|Takeda Pharmaceutical||47||Unlock Company Profile|
|United States Of America||47||Unlock Company Profile|
|AiCuris Anti-infective Cures||46||Unlock Company Profile|
|ONK Therapeutics||45||Unlock Company Profile|
|St. Jude Children’s Research Hospital||42||Unlock Company Profile|
|Io Therapeutics||41||Unlock Company Profile|
|Eureka Therapeutics||41||Unlock Company Profile|
|WindMIL Therapeutics||37||Unlock Company Profile|
|Geneius Biotechnology||37||Unlock Company Profile|
|Adicet Bio||36||Unlock Company Profile|
|Green Cross Holdings||36||Unlock Company Profile|
|TCR2 Therapeutics||35||Unlock Company Profile|
|Gamida Cell||35||Unlock Company Profile|
|CRISPR Therapeutics||34||Unlock Company Profile|
|Editas Medicine||34||Unlock Company Profile|
|Pfizer||34||Unlock Company Profile|
|Nuclear Threat Initiative||33||Unlock Company Profile|
|Massachusetts General Hospital||33||Unlock Company Profile|
|iCell Gene Therapeutics||33||Unlock Company Profile|
|Takara Holdings||33||Unlock Company Profile|
|Gracell Biotechnologies||32||Unlock Company Profile|
|Allogene Therapeutics||32||Unlock Company Profile|
|SanBio||32||Unlock Company Profile|
|TC BioPharm (Holdings)||30||Unlock Company Profile|
|Otsuka Holdings||30||Unlock Company Profile|
|BioNTech||29||Unlock Company Profile|
|PolyBioCept||29||Unlock Company Profile|
|Magenta Therapeutics||29||Unlock Company Profile|
|Eutilex||27||Unlock Company Profile|
|Precision Biosciences||27||Unlock Company Profile|
Source: GlobalData Patent Analytics
Immatics NV is a leading patent filer for cytotoxic T-cell based cancer immunotherapy. Its ACTengine programmes are based on genetically engineering a patient’s own, autologous T cells with novel TCRs designed to recognise the cancer target on the tumour. The company has several assets such as IMA203, IMA201 and IMA204. The company is working on TCR-based immunotherapies with an emphasis on treating various solid tumours.
In terms of application diversity, Abclon is the top company, followed by Dragonfly Therapeutics and Marengo Therapeutics. By means of geographic reach, EpiVax holds the top position, followed by Otsuka Holdings and Poseida Therapeutics, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.